Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 2/20 | 0.41 |
| ▸ | KLK7 | P49862 | 3/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | HRAS | P01112 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26878951 | 0.91 | L3MBTL1 (0.41) | SLC6A2L3MBTL1OGAKLK7KLK5 | |
| SCHEMBL14363001 | 0.91 | SLC6A2 (0.45) | SLC6A2L3MBTL1OGAKLK7KLK5 | |
| SCHEMBL26879054 | 0.89 | TP53 (0.42) | SLC6A2L3MBTL1KLK7KLK5BCHE | |
| SCHEMBL26879052 | 0.89 | TP53 (0.42) | SLC6A2L3MBTL1KLK7KLK5BCHE | |
| SCHEMBL404432 | 0.88 | LMNA (0.44) | L3MBTL1KLK7KLK5BCHEACACB | |
| SCHEMBL403009 | 0.85 | L3MBTL1 (0.38) | SLC6A2L3MBTL1OGAKLK7KLK5 | |
| SCHEMBL16211783 | 0.82 | SLC6A2 (0.47) | SLC6A2L3MBTL1KLK7KLK5BCHE | |
| SCHEMBL23705084 | 0.82 | TP53 (0.45) | L3MBTL1KLK7KLK5BCHETACR2 | |
| SCHEMBL23705152 | 0.82 | TP53 (0.45) | L3MBTL1KLK7KLK5BCHETACR2 | |
| SCHEMBL14363003 | 0.81 | LMNA (0.45) | L3MBTL1KLK7KLK5BCHEACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | HPSE, HAAO, HEXD | SLC6A2 2728/4885L3MBTL1 4789/4885OGA 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.